Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp le Coutre

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Haematologica|September 2, 2004
Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57Karl-Anton Kreuzer, Philipp le Coutre
Expert Opinion on Drug Safety|December 3, 2010
The expanding role of nilotinib in chronic myeloid leukemiaTheo Daniel Kim, Philipp le Coutre
Biomarker Insights|September 25, 2015
Emerging Role of Tyrosine Kinases as Drugable Targets in CancerIl-Kang Na, Philipp le Coutre
Acta Haematologica|May 26, 2023
The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular AnalysisThomas Burmeister, Lars Bullinger, Philipp le Coutre
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2010
New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemiaPhilipp le Coutre, Michaela Schwarz, Theo D Kim
Expert Review of Hematology|November 19, 2010
Nilotinib for the treatment of chronic myeloid leukemiaTheo Daniel Kim, Bernd Dörken, Philipp le Coutre
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
NilotinibMartin Gresse, Theo D Kim, Philipp le Coutre
Expert Opinion on Pharmacotherapy|September 16, 2011
Omacetaxine mepesuccinate for the treatment of leukemiaTheo Daniel Kim, Mareike Frick, Philipp le Coutre
Future Oncology (London, England)|December 14, 2019
The role of bosutinib in the treatment of chronic myeloid leukemiaCarlo Gambacorti-Passerini, Philipp le Coutre, Rocco Piazza
Clinical Advances in Hematology & Oncology : H&O|January 13, 2012
Post-transplantation chronic myeloid leukemiaPhilipp le Coutre, Michaela Schwarz, Peter Daniel, et al.
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Haematologica|September 2, 2004
Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57Karl-Anton Kreuzer, Philipp le Coutre
Expert Opinion on Drug Safety|December 3, 2010
The expanding role of nilotinib in chronic myeloid leukemiaTheo Daniel Kim, Philipp le Coutre
Biomarker Insights|September 25, 2015
Emerging Role of Tyrosine Kinases as Drugable Targets in CancerIl-Kang Na, Philipp le Coutre
Acta Haematologica|May 26, 2023
The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular AnalysisThomas Burmeister, Lars Bullinger, Philipp le Coutre
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2010
New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemiaPhilipp le Coutre, Michaela Schwarz, Theo D Kim
Expert Review of Hematology|November 19, 2010
Nilotinib for the treatment of chronic myeloid leukemiaTheo Daniel Kim, Bernd Dörken, Philipp le Coutre
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
NilotinibMartin Gresse, Theo D Kim, Philipp le Coutre
Expert Opinion on Pharmacotherapy|September 16, 2011
Omacetaxine mepesuccinate for the treatment of leukemiaTheo Daniel Kim, Mareike Frick, Philipp le Coutre
Future Oncology (London, England)|December 14, 2019
The role of bosutinib in the treatment of chronic myeloid leukemiaCarlo Gambacorti-Passerini, Philipp le Coutre, Rocco Piazza
Clinical Advances in Hematology & Oncology : H&O|January 13, 2012
Post-transplantation chronic myeloid leukemiaPhilipp le Coutre, Michaela Schwarz, Peter Daniel, et al.
Pageof 13